Depressive Mood Changes and Psychiatric Symptoms During 12-month Low-dose Interferon-α Treatment in Patients With Malignant Melanoma-Reference-Cited by-同舟云学术

Depressive Mood Changes and Psychiatric Symptoms During 12-month Low-dose Interferon-α Treatment in Patients With Malignant Melanoma

Published:2010-01 Issue:1 Volume:33 Page:106-114
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Heinze Sarah,Egberts Friederike,Rötzer Susanne,Volkenandt Matthias,Tilgen Wolfgang,Linse Ruthild,Boettjer Jörg,Vogt Thomas,Spieth Konstanze,Eigentler Thomas,Brockmeyer Norbert H.,Hinzpeter Axel,Hauschild Axel,Schaefer Martin

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference68 articles.

1. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma;Grob;Lancet,1998

2. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684;Kirkwood;J Clin Psychol,1996

3. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group;Pehamberger;J Clin Oncol,1998

4. Post-surgery adjuvant therapy with intermediate doses of interferon Alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial;Eggermont;Lancet,2005

5. Prognostic factors analysis of 17,600 melanoma patients: validation of the american joint committee on cancer melanoma staging system;Balch;J Clin Oncol,2001

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurological Impact of Type I Interferon Dysregulation;Rare Neurodegenerative Disorders - New Insights [Working Title];2024-07-31

2. Prevalence and odds of anxiety and depression in cutaneous malignant melanoma: a proportional meta-analysis and regression;British Journal of Dermatology;2024-01-10

3. Risk of developing psychiatric disease among adult patients with skin disease: A 9‐year national register follow‐up study in Norway;Skin Health and Disease;2023-10-20

4. Emerging concepts of type I interferons in SLE pathogenesis and therapy;Nature Reviews Rheumatology;2022-09-12

5. Examining the interrelationships between mindfulness‐based interventions, depression, inflammation, and cancer survival;CA: A Cancer Journal for Clinicians;2022-06-16